PFE
CELCpartner · Not moving with the group now
Filing receipt · PFE / CELC
“In April 2021, we obtained exclusive global development and commercialization rights to gedatolisib under a license agreement with Pfizer.”
CELC · partner
Confirmed
Clinical Biotechnology
9 names are moving together; 89% are participating in the current session.
1 observed Confirmed episode
Co-movement
Observed member paths adjusted against SPY. Shading marks the latest observation window.
Members
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | Healthcare | -2.5% | 1/3 observed active sessions |
| VERA | Vera Therapeutics, Inc. | Healthcare | -2.9% | 1/3 observed active sessions |
| GPCR | Structure Therapeutics Inc. | Healthcare | -3.0% | 2/3 observed active sessions |
| RVMD | Revolution Medicines, Inc. | Healthcare | -2.3% | 3/3 observed active sessions |
| WVE | Wave Life Sciences Ltd. | Healthcare | -4.2% | Group member |
| CLDX | Celldex Therapeutics, Inc. | Healthcare | -1.2% | 2/3 observed active sessions |
| TNGX | Tango Therapeutics, Inc. | Healthcare | -1.3% | Group member |
| IDYA | IDEAYA Biosciences, Inc. | Healthcare | -2.5% | Group member |
| CELC | Celcuity Inc. | Healthcare | -1.4% | 2/3 observed active sessions |
Why we believe this
Cohort
9 namesParticipation
89% this sessionObserved history
6 daily buildsThis identity theme becomes less useful if activity narrows to one or two names instead of remaining broad across the cohort.
Connected, outside the group
AMGN
IDYAinvestee · Not moving with the group now
Filing receipt · AMGN / IDYA
“These expenses are primarily for services provided by external consultants, CMOs and CROs.”
IDYA · investee
GILD
IDYApartner · Not moving with the group now
Filing receipt · GILD / IDYA
“We have also partnered with leading pharmaceutical companies, including GSK, Pfizer and Gilead to support clinical development activities for our pipeline programs.”
IDYA · partner
ARWR
WVEtext peer · Not moving with the group now
No filing excerpt is available for this relationship.
SGIOF
MAZEpartner · Current intraday read unavailable
Filing receipt · SGIOF / MAZE
“Except for the one-time, nonrefundable upfront payments we received pursuant to the license agreements we entered into with several biotechnology companies in 2024, incl…”
MAZE · partner
History
2026-07-27 → 2026-07-313 observed active sessions · 10% of active names held across the episode